VEGFA and diabetic macular edema: Anti-vascular endothelial growth factor (anti-VEGF) agents, including ranibizumab and aflibercept, can facilitate the regression of NV while eliminating diabetic macular edema (DME), and hence, are recommended for treating high-risk PDR patients (8, 9).